CN1205172C - Pravastatin sodium salt crystal - Google Patents
Pravastatin sodium salt crystal Download PDFInfo
- Publication number
- CN1205172C CN1205172C CNB008113653A CN00811365A CN1205172C CN 1205172 C CN1205172 C CN 1205172C CN B008113653 A CNB008113653 A CN B008113653A CN 00811365 A CN00811365 A CN 00811365A CN 1205172 C CN1205172 C CN 1205172C
- Authority
- CN
- China
- Prior art keywords
- pravastatin
- sodium salt
- ethyl acetate
- arbitrary
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, fluvastatin, cervastatin and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. Most of them are produced by fermentation with microorganisms of different species belonging to the genera Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium, some of them are obtained by treating the fermentation product by chemical synthesis, or they are products. The present invention relates to a novel crystalline form of the sodium salt of pravastatin having the chemical name 1, 2, 6, 7, 8, 8a-hexahydro- β, δ, 6-trihydroxy-2-methyl-8- (2-methyl-1-oxobutoxy) -1-naphthaleneptanoic acid monosodium salt (1-naphthaleneheptanoid acid, 1, 2, 6, 7, 8, 8a-hexahydro- β, δ, 6-trihydroxy-2-methyl-8- (2-methyl-1-oxoutoxy) -, mono sodium salt) which is useful as a medicament, to processes for its preparation and isolation, and to pharmaceutical formulations and methods of medical treatment containing the crystalline form of the sodium salt of pravastatin. The novel crystalline form of the sodium salt of pravastatin is useful in the treatment of hypercholesterolemia and hyperlipidemia.
Description
The present invention relates to the crystalline form of sodium salt of pravastatin, its chemistry is called 1,2,6,7,8,8a-six hydrogen-β, and δ, 6-trihydroxy--2-methyl-8-(2-methyl isophthalic acid-oxygen butoxy)-1-naphthalene enanthic acid list sodium salt, it is useful as medicine.The invention further relates to its preparation and separation method, and relate to the sodium salt of pravastatin that contains crystalline form and the formula of medicine of pharmaceutically acceptable carrier, and relate to drug treatment.
The known HMG-CoA of the being reductase inhibitor of lovastatin, Pravastatin, Simvastatin, mevastatin, atorvastatin, fluvastatin, cervastatin and derivative thereof and analogue also is used as antihypercholesterolemic.Major part in them is by producing with the different plant species microbial fermentation that belongs to Aspergillus, red colouring agent for food, also used as a Chinese medicine genus, nocardia, amycolatosis genus, mucor or Penicillium, in them some obtain (Simvastatin) by handling tunning with the method for chemosynthesis, and perhaps they are products (fluvastatin, atrorvastatin and cervastatin) of full chemosynthesis.
The preparation method of the sodium salt of pravastatin of known solid form comprises in the prior art, for example, and the lyophilize step.After the lyophilize, have only solvent to be removed, and impurity stay with sodium salt of pravastatin.Except that the above, lyophilize is not too economical in the scale operation operation.Because method is non-selective, impurity and expectation material coprecipitation during precipitating.Compare with the preparation method of the medicine of above-mentioned two kinds of solid forms, crystallization is unique process for selective, expects that wherein the molecule of material is optionally introduced crystal matrix.The possibility that contains impurity in the crystal is very little, because have only the molecule of small volume just can enter intracrystalline intermolecular space (related impurities in expectation material volume range is difficult to enter this space usually), for the crystal matrix that enters of other molecule, aspect thermodynamics, be disadvantageous.
Compare with amorphous structure, the advantage of crystalline structure is that its physical and chemical parameter is more definite, and they are more stable.For unstable under the native state, for the material of different surrounding environment influence sensitivities, back one characteristic is particularly important, surrounding environment influence such as light, pH, atmosphere and Temperature Influence.Pravastatin sodium is extremely responsive to these negative impacts.
Known sodium salt of pravastatin so far can only exist with amorphous form.Describing sodium salt of pravastatin among the Merck Index1996 is amorphous substance.
The preparation method of sodium salt of pravastatin all has description in many patents, for example United States Patent (USP) 44,537, and 859, United States Patent (USP) 4,448,979, United States Patent (USP) 4,410, and 629 and United States Patent (USP) 4,346,227, these methods have only realized the preparation method of amorphous form.In disclosed method, after the chromatographic column separation, the part that contains sodium salt of pravastatin of gained is carried out lyophilize, obtain the sodium salt of solid-amorphous form.
WO-A-98/45410 discloses with behind the reverse-phase chromatography purification of pravastatin sodium salt, can obtain so-called crystal by precipitation in ethanol/ethyl acetate mixture; But the test that we have carried out shows that this solvent combination only realizes the Pravastatin of preparation amorphous form, rather than the Pravastatin of crystalline form.
The purpose of this invention is to provide sodium salt of pravastatin, compare its purity and improved stability with the salt of describing in the above-mentioned prior art.
Another object of the present invention provides the preparation method of this sodium salt of pravastatin.
These and other objects are realized by the present invention.
In first aspect, the invention provides the sodium salt of pravastatin of crystalline form.In addition, the present invention also provides the sodium salt of pravastatin of particular crystalline, wherein said crystal in X-ray diffraction is measured, produce with the diffractogram shown in Fig. 2 in signal like the class signal that shows.
In second aspect, the invention provides the preparation method of the sodium salt of pravastatin of crystalline form, said method comprising the steps of: (a) in lower aliphatic alcohols, dissolve sodium salt of pravastatin; (b) in the sodium salt of pravastatin alcoholic solution, add ethyl acetate; (c) cool off described alcohol/ethyl acetate mixture; (d) crystallization.
According to a third aspect of the invention we, the present invention further provides the formula of medicine of the sodium salt of pravastatin that contains above-mentioned crystalline form.
Crystal sodium salt of pravastatin according to the present invention is particularly suitable for preparing the medicament production that is used for the treatment of hypercholesterolemia and hyperlipidaemia.
Below accompanying drawing will be described briefly.
Fig. 1: the diffractogram of the amorphous sodium salt of pravastatin of commercial routine, with x-ray powder diffraction instrument scanning, 2 θ scopes (range) are 2-42 °, and 2 θ step-lengths (step) are 0.025 °, and be 1 second/step integral time.
Fig. 2: according to the diffractogram of the crystals of sodium salt of pravastatin of the embodiment of the invention 2 preparation, with X-ray diffractometer scanning, 2 θ scopes are 2-48 °, and 2 θ step-lengths are 0.035 °, and be 1 second/step integral time.
Fig. 3: be used for the image of the amorphous sodium salt of pravastatin of Fig. 1 X-ray diffraction mensuration, it ties up to microscopically and amplifies 400 times of gained.
Fig. 4: according to the image of the crystals of sodium salt of pravastatin of the embodiment of the invention 2 preparation, it ties up to microscopically and amplifies 400 times of gained.
Carry out X-ray diffraction with x-ray powder diffraction instrument (Phillips PW 1710) and measure, use Cu-K
α(20mA, 40kV, λ=1.5406 ) light source.In order to carry out microscopic examination, use OLYMPUS BX 50F microscope, it has CCD SonnyDXC-950-P photographic camera, and ratio of enlargement is 400 times.
Below will be for a more detailed description to the present invention by the description of preferred embodiment.
In our research work, we are surprised to find, and by selecting suitable solvent and correct solvent use order, can prepare the sodium salt of pravastatin of certain form, and with respect to conventional solid form, form of the present invention has the degree of crystallinity of improvement.Therefore, compare with the white appearance of sodium salt of pravastatin described in the WO-A-98/45410,, may obtain presenting the crystal of colourless or light yellow outward appearance according to the present invention, this clearly illustrates that the degree of crystallinity of improvement, the sodium salt of pravastatin of crystalline transparent form provided by the invention that Here it is.
Other physical properties of the crystalline of Pravastatin sodium of the present invention further shows the degree of crystallinity of the improvement of gained.At first, crystal of the present invention can be preferably with the needle-like form, and the form with radiation bunch obtains sometimes.This crystal shape can be observed at microscopically with removing, for example amplifies 400 times and observes (see figure 4).Comparatively speaking, conventional amorphous Pravastatin sodium is particulate state shape (see figure 3).
Secondly, the fusing point of crystals of sodium salt of pravastatin of the present invention is preferably between 170-174 ℃, more preferably between 172-174 ℃.For the chemical structure of complexity like this, the melting range that the present invention realizes is very narrow, confirms the Pravastatin sodium crystalline high-crystallinity of gained.
The 3rd, another characteristic of crystal Pravastatin sodium of the present invention is to measure (Cu-K at X-ray diffraction
α, 29) in the signal that obtains have sharp-pointed isolating peak.Especially, the shape at the X-ray diffraction peak of Pravastatin sodium of the present invention is defined by little " half breadth ", and this has confirmed the degree of crystallinity that it is high.2 θ value ranges when term " half breadth " refers to half peak heights at a certain peak.So the signal that obtains with these mensuration comprises isolating peak (2 θ), their half breadth more preferably below 1 °, most preferably is below 0.5 ° preferably below 2 °.
The diffractogram that the Pravastatin sodium crystal of example prepared in accordance with the present invention produces in X-ray diffraction is measured is shown in Fig. 2.Because its degree of crystallinity, purity and stability are improved greatly, measure (Cu-K at X-ray diffraction
α) in produce with diffractogram shown in Figure 2 in like the class signal that shows the Pravastatin sodium crystal of signal constitute embodiment preferred of the present invention.Because size and high background during ° 2 θ of its angle＞20, this crystalline structure cell can't be determined.The diffractogram of record with from PDF and CSD database (PDF-" by " International Center for Diffraction Data "; 12Campus Boulevard; Newtown Square, the Power Diffraction File of PA 19073-3273 USA distribution "; The relatively demonstration of document CSD-" by " CambridgeCrystallographic Data Centre "; 12 Union Road; Cambridge CB2 1EZ; the CambridgeCrystallographic Data Centre of the United Kingdom distribution "), a kind of really new and crystalline form that be unique known sodium salt of pravastatin of crystals of sodium salt of pravastatin of the present invention.In contrast, the diffractogram of commercial amorphous Pravastatin sodium is shown in Fig. 1.
The crystal preparation method of the invention described above may further comprise the steps:
(a) provide the lower aliphatic alcoholic solution that contains Pravastatin and sodium cation.This is by solid and/or amorphous sodium salt of pravastatin being dissolved in the lower aliphatic alcohols that preferably has 1-4 carbon atom and suitably carry out.More preferably, the alcohol that is used for dissolving Pravastatin sodium is ethanol or methyl alcohol.When preparing the methanol solution of Pravastatin sodium, obtain best crystallization result.
(b) in alcoholic solution, add ethyl acetate, the preferred alcoholic solution of continuously stirring step (a) gained simultaneously.In the Pravastatin sodium ethoxide solution, add ethyl acetate and preferably carry out lentamente, can add continuously or in batches.
(c) alcohol/ethyl acetate mixture of cooling gained.
(d) crystallization.
In step (d), crystals of sodium salt of pravastatin forms from the refrigerative mixture, and it preferably presents colourless or light yellow outward appearance, and be needle-like or the radiation bunch form.
In addition, preferably will filter with the crystal of this method gained, with ethyl acetate washing and drying.
If meet following condition, to help crystallization, be sodium salt of pravastatin at the starting point concentration that is used for the dissolved lower aliphatic alcohols preferably between 0.03-0.3g/ml, 0.05-0.2g/ml more preferably, particularly about 0.1g/ml, and the ethyl acetate volume that is added in the step (b) preferably is no more than 15 times of initial sodium salt of pravastatin lower aliphatic alcohols liquor capacity, more preferably no more than its 10 times.
In addition, in order to realize higher percent crystallization in massecuite, preferred Tc is for being lower than 15 ℃, more preferably less than 10 ℃, and particularly about 8 ℃.
For forcing further crystallization,, preferably implement to take when of the present invention following additional step according to the present invention:
(e) in the mixture of step (d), further add ethyl acetate.This carries out behind the appropriate time that crystalline first crystallisation stage takes place.
(f) then, continue the crystallization of Pravastatin sodium simultaneously at refrigerative.
After stage, the yield of crystal Pravastatin sodium can increase, and increases 5-10% usually through this additional crystallization.
With the volumeter of the ethyl acetate of adding in the step (b), the volume range of the ethyl acetate that further adds in the refrigerative mixture in step (e) is 25-75% (volume), more preferably 40-60% (volume) preferably.
In addition, crystal formation total crystallization time is preferably between 3-20 hour.More preferably, total crystallization time is 4-12 hour, especially about 4 hours.
The invention still further relates to the formula of medicine of the sodium salt of pravastatin that contains crystalline form.Formula of medicine can be respectively to be used for oral and form parenteral introduction exists, it is used for the treatment of hypercholesterolemia and hyperlipidaemia.Formula of medicine of the present invention can be tablet, capsule, granule and suppository and suspension liquor.
Formula of medicine of the present invention is except containing sodium salt of pravastatin, can also comprise one or more fillers, as Microcrystalline Cellulose, lactose, sucrose, starch, treated starch, N.F,USP MANNITOL, Sorbitol Powder and other polyvalent alcohol, dextrin, dextran and Star Dri 5, lime carbonate, calcium phosphate and/or hydrophosphate, vitriol, one or more tackiness agents, as lactose, starch, treated starch, dextrin, dextran and Star Dri 5, Microcrystalline Cellulose, sucrose, polyoxyethylene glycol, hydroxypropylcellulose, Vltra tears, ethyl cellulose, Natvosol, methylcellulose gum, carboxymethyl cellulose, gelatin, gum arabic, tragacanth gum, polyvinylpyrrolidone, neusilin, one or more disintegrating agents, as croscarmellose sodium, cross-linked polyvinylpyrrolidone, crosslinked carboxymethyl fecula, starch and Microcrystalline Cellulose, neusilin, polyacrylic acid potassium, the glidant that one or more are different, as Magnesium Stearate, calcium stearate, Zinic stearas docosoic calcium, sodium stearyl fumarate, talcum powder, Magnesium Trisilicate, stearic acid, palmitinic acid, babassu is cured, silicon-dioxide, one or more buffer reagents are as Sodium Citrate or potassium, sodium phosphate, Sodium phosphate dibasic, lime carbonate, hydrophosphate, phosphoric acid salt, vitriol, yellow soda ash or magnesium, ascorbinate sodium, benzoate, sodium bicarbonate or potassium, the mixture of lauryl sulfate or these buffer reagents.
If desired, can also comprise tensio-active agent in the prescription and be used for the conventional composition of solid medicament formulations, as tinting material, color lake, perfume compound and sorbent material with other.Can use down surfactant: ionic surface active agent, as sodium lauryl sulphate, or nonionogenic tenside, as different poloxamer (polyoxyethylene and polyoxypropylene copolymer), natural or synthetic Yelkin TTS, sorbitan ester and lipid acid (as Span
, AtlasChemie produces), polyoxyethylene sorbitan and lipid acid is (as Tween
AtlasChemie production), polyoxy ethyl hydrogenated castor oil is (as Cremophor
, BASF produces), polyoxyethylene stearic acid ester is (as Brij
, Atlas Chemie produces), the combination of dimethyl polysiloxane or above-mentioned tensio-active agent.
If solid medicament formulations is a coated tablet, dressing can be by at least a membrane-forming agent preparation, membrane-forming agent such as Vltra tears, hydroxypropylcellulose, has a kind of softening agent at least, be used for film-coated conventional medicine auxiliary substance as polyoxyethylene glycol, Uniflex DBS, citric acid triethyl ester and other, as pigment, filler and other.
Formula of medicine can be by conventional formulation method preparation well known by persons skilled in the art.
The present invention explains by following examples, but is not limited thereto.
Embodiment 1
Sodium salt of pravastatin (1 gram) is dissolved in methyl alcohol (10 milliliters), under agitation adds ethyl acetate.Gained yellow transparent solution is cooled to 8 ℃, and placement is spent the night.With the elongated needle-like crystalline radiation bunch filtration that forms, with ethyl acetate (20 milliliters) washing and dry.Yield: 0.87 gram pale yellow crystals, fusing point is 172-174 ℃.
Embodiment 2
Sodium salt of pravastatin (2 gram) is dissolved in methyl alcohol (20 milliliters), under agitation adds ethyl acetate (80 milliliters).Transparent pale yellow solution is cooled to 8 ℃, placed 4 hours.With the elongated needle-like crystalline radiation bunch filtration that forms, with ethyl acetate (20 milliliters) washing and dry.Yield: 1.53 gram clear crystals, fusing point is 172-174 ℃.
Embodiment 3
Sodium salt of pravastatin (2 gram) is dissolved in methyl alcohol (20 milliliters), under agitation adds ethyl acetate (150 milliliters).The transparent pale yellow solution of gained is cooled to 8 ℃, placed 4 hours.With the elongated needle-like crystalline radiation bunch filtration that forms, with ethyl acetate (20 milliliters) washing and dry.Yield: 1.66 gram clear crystals, fusing point is 172-174 ℃.
Sodium salt of pravastatin (2 gram) is dissolved in methyl alcohol (20 milliliters), under agitation adds ethyl acetate (170 milliliters).The transparent pale yellow solution of gained is cooled to 8 ℃, placed 4 hours.With the elongated needle-like crystalline radiation bunch filtration that forms, with ethyl acetate (20 milliliters) washing and dry.Yield: 1.75 gram clear crystals, fusing point is 172-174 ℃.
Embodiment 5
Sodium salt of pravastatin (2 gram) is dissolved in methyl alcohol (12 milliliters), under agitation adds ethyl acetate (100 milliliters).The transparent pale yellow solution of gained is cooled to 8 ℃, placed 1 hour.After further adding ethyl acetate (60 milliliters) again, force the Pravastatin crystallization that still is dissolved in the solution.Place 8 ℃ after 2 hours, with the elongated needle-like crystalline radiation bunch filtration that forms, with ethyl acetate (20 milliliters) washing and dry.Yield: 1.85 gram clear crystals, fusing point is 172-174 ℃.
Claims (18)
1. the sodium salt of pravastatin of crystalline form, wherein said crystal in X-ray diffraction is measured, produce with diffractogram shown in Figure 2 in the identical signal of signal that shows.
2. according to the sodium salt of pravastatin of claim 1, wherein said crystal presents colourless or light yellow outward appearance.
3. according to the sodium salt of pravastatin of claim 1 or 2, wherein said crystal presents pellucidly with the form of needle-like or radiation bunch.
4. according to the sodium salt of pravastatin of arbitrary claim among the claim 1-3, wherein melting range is 170 ℃-174 ℃.
5. according to the sodium salt of pravastatin of arbitrary claim among the claim 1-4, wherein crystal generation half breadth in X-ray diffraction is measured is lower than 2 ° the isolating peak at 2 θ angles.
6. prepare the method for the sodium salt of pravastatin of crystalline form, said method comprising the steps of:
(a) provide the lower aliphatic alcoholic solution that contains Pravastatin and sodium cation with 1-4 carbon atom;
(b) in the alcoholic solution of the described 1-4 of a having carbon atom, add ethyl acetate;
(c) cool off described alcohol/ethyl acetate mixture; And
(d) crystallization.
7. according to the method for claim 6, it further may further comprise the steps behind first crystallisation stage:
(e) in alcohol/ethyl acetate mixture, further add ethyl acetate;
(f) further crystallization.
8. according to the method for claim 6 or 7, wherein lower aliphatic alcohols is ethanol or methyl alcohol.
9. according to the method for claim 6 or 7, wherein lower aliphatic alcohols is a methyl alcohol.
10. according to the method for arbitrary claim among the claim 6-9, wherein in continuously stirring sodium salt of pravastatin alcoholic solution, add ethyl acetate.
11. according to the method for arbitrary claim in claim 6 or 10, wherein the middle concentration of sodium salt of pravastatin in alcoholic solution of step (a) is between 0.03-0.3g/ml.
12. according to the method for arbitrary claim among the claim 6-11, wherein the volume of added ethyl acetate is no more than 15 times of initial sodium salt of pravastatin alcoholic solution volume in the step (b).
13. according to the method for arbitrary claim among the claim 7-12, wherein to be added the volumeter of ethyl acetate in the step (b), the volume range of the ethyl acetate that further adds in the step (e) is 25-75 volume %.
14., wherein alcohol/ethyl acetate mixture is cooled to temperature and is lower than 15 ℃ according to the method for arbitrary claim among the claim 6-13.
15. according to the method for arbitrary claim among the claim 6-14, wherein total crystallization time is between 3-20 hour.
16. according to the method for arbitrary claim among the claim 6-15, wherein the crystal that forms is filtered, with ethyl acetate washing and drying.
17. a formula of medicine, it contains the sodium salt of pravastatin of the crystalline form of arbitrary claim among the claim 1-5.
18. the purposes of crystal sodium salt of pravastatin in the preparation of the medicament production that is used for the treatment of hypercholesterolemia and hyperlipidaemia of arbitrary claim among the claim 1-5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SLP9900191 | 1999-08-06 | ||
| SI9900191A SI20305A (en) | 1999-08-06 | 1999-08-06 | Pravastatin sodium salt crystals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1368948A CN1368948A (en) | 2002-09-11 |
| CN1205172C true CN1205172C (en) | 2005-06-08 |
Family
ID=20432515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008113653A Expired - Fee Related CN1205172C (en) | 1999-08-06 | 2000-08-04 | Pravastatin sodium salt crystal |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7078558B1 (en) |
| EP (1) | EP1200385B2 (en) |
| JP (1) | JP2003506424A (en) |
| KR (2) | KR100766928B1 (en) |
| CN (1) | CN1205172C (en) |
| AT (1) | ATE287389T1 (en) |
| BG (1) | BG65368B1 (en) |
| CA (1) | CA2379335A1 (en) |
| CZ (1) | CZ2002414A3 (en) |
| DE (1) | DE60017568T2 (en) |
| DK (1) | DK1200385T3 (en) |
| ES (1) | ES2235911T5 (en) |
| HR (1) | HRP20020106A2 (en) |
| HU (1) | HUP0202536A3 (en) |
| IL (3) | IL148050A0 (en) |
| NZ (1) | NZ516685A (en) |
| PL (1) | PL365850A1 (en) |
| PT (1) | PT1200385E (en) |
| RU (1) | RU2247711C2 (en) |
| SI (2) | SI20305A (en) |
| SK (1) | SK1742002A3 (en) |
| WO (1) | WO2001010813A1 (en) |
| YU (1) | YU5402A (en) |
| ZA (1) | ZA200200437B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20305A (en) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Pravastatin sodium salt crystals |
| SI20070A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE |
| WO2001043723A1 (en) | 1999-12-14 | 2001-06-21 | Biogal Gyogyszergyar Rt. | Novel forms of pravastatin sodium |
| JP2002121172A (en) * | 2000-10-16 | 2002-04-23 | Sankyo Co Ltd | Method for purifying pravastatin or pharmacologically acceptable salt thereof |
| JP3236282B1 (en) * | 2000-10-16 | 2001-12-10 | 三共株式会社 | How to purify pravastatin |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US6716615B2 (en) | 2002-02-27 | 2004-04-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase |
| JP4308021B2 (en) | 2002-03-18 | 2009-08-05 | バイオコン・リミテッド | Amorphous HMG-CoA reductase inhibitors with desirable particle size |
| WO2004110585A1 (en) * | 2003-06-10 | 2004-12-23 | Taisho Pharmaceutical Co., Ltd. | Radial spherical crystallization product, process for producing the same and dry powder preparation containing the crystallization product |
| CN1293874C (en) * | 2003-08-18 | 2007-01-10 | 李朝晖 | Traditional chinese medicine Monascus purpureus went using Lovastatin salt as main active and its preparation component |
| DE602004017461D1 (en) | 2003-11-24 | 2008-12-11 | Teva Gyogyszergyar Zartkoeruen | PROCESS FOR CLEANING PRAVASTATIN |
| US20080242725A1 (en) * | 2004-03-01 | 2008-10-02 | Janez Kerc | Pharmaceutical Composition |
| MX2007001558A (en) * | 2004-08-06 | 2008-03-13 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment. |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| JP2008509154A (en) | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | Novel statin drug compositions and related treatment methods |
| CA2595635A1 (en) * | 2005-02-09 | 2006-08-17 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Methods of making pravastatin sodium |
| JP4895510B2 (en) * | 2005-02-23 | 2012-03-14 | 株式会社トクヤマ | Method for producing variolamine |
| JP4813841B2 (en) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | Method for producing pravastatin sodium |
| US20110112053A1 (en) * | 2008-04-16 | 2011-05-12 | University Of Utah Research Foundation | Pharmacological targeting of vascular malformations |
| CN101348476B (en) * | 2008-09-05 | 2011-05-11 | 丽珠集团新北江制药股份有限公司 | Method for preparing 4,5,6,7-tetrahydromevastatin and sodium salt thereof, and solid crystallization way |
| CN101648867B (en) * | 2009-09-04 | 2012-07-11 | 天津大学 | A kind of crystal form of pravastatin sodium and its preparation method and application |
| EP2343054A1 (en) | 2010-01-04 | 2011-07-13 | LEK Pharmaceuticals d.d. | Pellets and microparticles of pravastatin sodium and a process of making them |
| CN102533893A (en) * | 2010-12-09 | 2012-07-04 | 浙江海正药业股份有限公司 | Method for preparing monacolin J |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX7065E (en) * | 1980-06-06 | 1987-04-10 | Sankyo Co | A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B |
| JPS572240A (en) * | 1980-06-06 | 1982-01-07 | Sankyo Co Ltd | Ml-236b derivative |
| JPS5889191A (en) * | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | Preparation of 3-hydroxy-ml-236b derivative |
| CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
| KR100210482B1 (en) * | 1997-04-10 | 1999-07-15 | 김종인 | STREPTOMYCESEXFOLIATUS YJ-118 and Method for Preparing Sodium Pravastatin |
| US6098031A (en) | 1998-03-05 | 2000-08-01 | Gsi Lumonics, Inc. | Versatile method and system for high speed, 3D imaging of microscopic targets |
| SI20072A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | PROCEDURE OF PREPARATION OF INHIBITORS OF HMG-CoA REDUCTASE |
| SI20070A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE |
| SI20305A (en) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Pravastatin sodium salt crystals |
| HRP20010577B1 (en) † | 1999-02-03 | 2005-12-31 | Institute For Drug Research Ltd. | Microbial process for preparing pravastatin |
| US6682913B1 (en) * | 1999-02-03 | 2004-01-27 | Institute For Drug Research Ltd. | Microbial process for preparing pravastatin |
-
1999
- 1999-08-06 SI SI9900191A patent/SI20305A/en not_active IP Right Cessation
-
2000
- 2000-08-04 DE DE60017568T patent/DE60017568T2/en not_active Expired - Lifetime
- 2000-08-04 SK SK174-2002A patent/SK1742002A3/en not_active Application Discontinuation
- 2000-08-04 CZ CZ2002414A patent/CZ2002414A3/en unknown
- 2000-08-04 RU RU2002102862/04A patent/RU2247711C2/en not_active IP Right Cessation
- 2000-08-04 DK DK00946239T patent/DK1200385T3/en active
- 2000-08-04 HR HR20020106A patent/HRP20020106A2/en not_active Application Discontinuation
- 2000-08-04 WO PCT/IB2000/001103 patent/WO2001010813A1/en not_active Ceased
- 2000-08-04 ES ES00946239T patent/ES2235911T5/en not_active Expired - Lifetime
- 2000-08-04 CN CNB008113653A patent/CN1205172C/en not_active Expired - Fee Related
- 2000-08-04 NZ NZ516685A patent/NZ516685A/en not_active IP Right Cessation
- 2000-08-04 CA CA002379335A patent/CA2379335A1/en not_active Abandoned
- 2000-08-04 YU YU5402A patent/YU5402A/en unknown
- 2000-08-04 KR KR1020027001231A patent/KR100766928B1/en not_active Expired - Fee Related
- 2000-08-04 PL PL00365850A patent/PL365850A1/en not_active Application Discontinuation
- 2000-08-04 PT PT00946239T patent/PT1200385E/en unknown
- 2000-08-04 HU HU0202536A patent/HUP0202536A3/en unknown
- 2000-08-04 IL IL14805000A patent/IL148050A0/en unknown
- 2000-08-04 EP EP00946239A patent/EP1200385B2/en not_active Expired - Lifetime
- 2000-08-04 JP JP2001515281A patent/JP2003506424A/en active Pending
- 2000-08-04 SI SI200030653T patent/SI1200385T2/en unknown
- 2000-08-04 US US10/049,093 patent/US7078558B1/en not_active Expired - Fee Related
- 2000-08-04 KR KR1020077015051A patent/KR20070086847A/en not_active Withdrawn
- 2000-08-04 AT AT00946239T patent/ATE287389T1/en not_active IP Right Cessation
-
2002
- 2002-01-17 ZA ZA200200437A patent/ZA200200437B/en unknown
- 2002-02-05 BG BG106389A patent/BG65368B1/en unknown
- 2002-02-06 IL IL148050A patent/IL148050A/en not_active IP Right Cessation
-
2003
- 2003-04-04 US US10/408,012 patent/US6740775B1/en not_active Expired - Fee Related
-
2006
- 2006-04-10 US US11/400,872 patent/US20060183929A1/en not_active Abandoned
-
2007
- 2007-11-08 IL IL187261A patent/IL187261A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1205172C (en) | Pravastatin sodium salt crystal | |
| CN1198597C (en) | Stable pharmaceutical formulations containing HMG-CoA reductase inhibitors | |
| RU2134690C1 (en) | Acetamido-2,3,4,5-tetradioxy-4-gyanidino-d-glycero-d- galactonone-2-enopyranozonic acid in crystalline form, preparation methods, pharmaceutical composition, and method of preparing thereof | |
| CN1633439A (en) | Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent | |
| CN1443182A (en) | Process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities | |
| US20080300305A1 (en) | Method of purifying pravastatin | |
| AU782143B2 (en) | Crystals of the sodium salt of pravastatin | |
| JPWO2003026645A1 (en) | Crystals of tetrapeptide derivatives | |
| CA2425882A1 (en) | Method of purifying pravastatin or its pharmacologically acceptable salt | |
| KR101101319B1 (en) | Purification of impure amorphous pravastatin sodium salt to produce crystalline pravastatin sodium salt | |
| AU2013204129B2 (en) | Crystal Form of Quinoline Compound and Process for its Production | |
| CZ2005573A3 (en) | Process for preparing crystalline form of (3R, 5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropylpyrrol-1-yl]-3,5 dihydroxyheptanoic acid hemi-calcium salt (atorvastatin) | |
| MXPA06005819A (en) | Method of purifying pravastatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050608 Termination date: 20130804 |